Physician profile
Lorena Kuschel
NPI 1043724321
$3,427.18
in general payments reported to CMS, 2019-2025
29 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 97% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $796 · 2023: $739 · 2024: $563 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.95 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $407.13 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $304.34 | 2021-2025 | |
| Astellas Pharma US INC | $249.72 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $197.56 | 2023-2025 | Myfembree, Gemtesa |
| Biotissue Holdings INC. | $194.56 | 2025 | |
| Myovant Sciences INC. | $182.84 | 2021-2022 | |
| Viiv Healthcare Company | $156.58 | 2024-2025 | Apretude |
| Coopersurgical, INC. | $151.78 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Pharmacosmos Therapeutics INC. | $127.31 | 2025 | Monoferric |
| Cumberland Pharmaceuticals, INC. | $121.83 | 2021-2023 | Kristalose |
| Exeltis, USA INC. | $112.05 | 2023-2025 | Slynd |
| Organon LLC | $110.68 | 2022-2025 | Nexplanon |
| Millicent US INC | $96.29 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $91.52 | 2022-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $60.19 | 2022 | |
| Agile Therapeutics, INC. | $55.96 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $55.23 | 2022-2023 | Seglentis |
| Pfizer INC. | $50.61 | 2023-2024 | |
| Davol INC. | $49.58 | 2025 | Arista |
| Biogen, INC. | $36.39 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $23.45 | 2024 | Gardasil 9, Gardasil |
| Mission Pharmacal Company | $22.61 | 2023 | Citranatal |
| Abbott Laboratories | $20.46 | 2024 | Proclaim |
| Ethicon US, LLC | $19.74 | 2024 | Vistaseal |
| Optumhealth Care Solutions, LLC | $18.61 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Mycovia Pharmaceuticals, INC. | $17.40 | 2023 | Vivjoa |
| Evofem Biosciences, INC. | $16.31 | 2021 | |
| Lupin INC. | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Kuschel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.